US Markets are Currently Closed - 11/22/2009 at 3:45:54 AM EST Market Indexes: SPY $109.43 (0.36%) DIA $103.25 (0.06%) QQQQ $43.44 (0.50%) Biggest Gains: PALG $22.92 (14.60%) PCS $6.52 (6.54%) NMR $6.84 (6.21%) DBRN $21.68 (5.65%) SVR $16.75 (5.61%) Biggest Losses: DHI $10.37 (15.35%) DELL $14.29 (9.96%) NUVA $33.80 (9.02%) SBAY $14.00 (8.08%) CEA $35.76 (5.80%) Recently Viewed Stocks: AOB $3.77 (0.26%) GS $170.01 (1.63%) MSFT $29.62 (0.54%) PJF $21.30 (0.02%) PVCT $1.07 (1.90%)

PROVECTUS PHARMACEUTICAL (OTCBB: PVCT)

0.02 (1.90%)

$1.07

Real-time: $1.07 0.02 (1.90%) 12:00:00 AM ET

Quote Charts Option Chain News Historical Executives Earnings Ratios Statement Balance Sheet Cash Flow

You need to upgrade your Flash Player to view the graph.

View Advanced Charts

View by Date Range:

Are you Bullish or Bearish on PVCT?

Investors are 50% Bullish and 50% Bearish on PVCT

Key Stats

Market Cap

0.07 B

Diluted EPS (TTM)

-0.14

P/E Ratio (TTM)

0.0

52-Week High Price

1.33

52-Week Low Price

0.67

Avg Volume (3 Mo.)

0.00 M

Beta

1.11

64.91 M

Dividend Rate ($)

0.00

Dividend Rate (%)

0.00

12 Mo. Price Change : N/A

Click Here For Free Annual Reports

Similar Companies

Name	Most Recent Price	Today's Change	Market Cap
WEIKANG BIO-TECH GP CO (WKBT)	$2.75	$0.04(1.43%)	0.07 B
ADOLOR CORP (ADLR)	$1.51	$0.01(0.67%)	0.07 B
IMMUNOSYN CORP (IMYNE)	$0.28	$0.02(7.69%)	0.07 B
CARDIOVASCULAR SYSTEMS (CSII)	$5.07	$0.36(7.64%)	0.07 B
SCHIFF NUTRITION INTL (WNI)	$5.51	$0.11(2.04%)	0.07 B
ARYX THERAPEUTICS INC (ARYX)	$2.46	$0.03(1.23%)	0.07 B
THRESHOLD PHARMACEUTICAL (THLD)	$2.03	$0.05(2.53%)	0.07 B
ASPENBIO PHARMA INC (APPY)	$1.66	$0.02(1.20%)	0.06 B
IMMUNOSYN CORP (IMYN)	$0.26	$0.03(13.04%)	0.06 B
ADVANCED CELL TECH INC (ACTC)	$0.11	$0.01(8.00%)	0.06 B

PVCT Headlines
More Stock Ideas

Enrollment in Provectus’ Phase 2 Melanoma Clinical Trial Reaches Halfway Point
Enrollment in Provectus’ Phase 2 Melanoma Clinical Trial Reaches Halfway Point
At BusinessWire 11/25/2008

Provectus to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008
Provectus to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008
At BusinessWire 11/24/2008

Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Melanoma Study at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting
Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Melanoma Study at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting
At BusinessWire 11/20/2008

Provectus Lead Investigator Professor John F. Thompson to Present at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting on November 19, 2008
Provectus Lead Investigator Professor John F. Thompson to Present at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting on November 19, 2008
At BusinessWire 11/18/2008

Provectus Pharmaceuticals Adds Sixth Center to Phase 2 Clinical Trial of PV-10
Provectus Pharmaceuticals Adds Sixth Center to Phase 2 Clinical Trial of PV-10
At BusinessWire 11/17/2008

Provectus Scheduled to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Provectus Scheduled to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
At BusinessWire 11/4/2008

View All Headlines